aod9604 weight loss evidence safety Understanding AOD 9604: The Science of the “Fat-Burning” Peptide Fragment Molecular Biology 5 amino 1mq side Usage Period:90 days
5 amino 1mq side effects liver Peptide Therapy Reduced calorie diet combined with –
Summary CJC-1295, Ipamorelin, and Tesamorelin are typically compounded together due to their ability to stimulate GHRH for enhanced results
Molecular Biology
Usage Period:90 days
Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, “weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of ≥30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of ≥27 with concomitant obesity-related risk factors or diseases”[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]
